Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature Mariano MalaguarneraLaura FerlitoGiovanni Pistone Review Pages: 267 - 273
Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine K. Breithaupt-Grögler W. Ungethüm G. Belz Pharmacodynamics Pages: 275 - 284
No correlations between the urinary ratio of 6β-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam N. Yasui-Furukori T. Kondo S. Kaneko Pharmacokinetics and Disposition Pages: 285 - 288
Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients P. Lohmann M. Rao M. Bagli Pharmacokinetics and Disposition Pages: 289 - 295
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children A. Patoux N. Bleyzac E. Chatelut Pharmacokinetics and Disposition Pages: 297 - 303
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel M. Malingré W. Ten Bokkel Huinink J. Beijnen Pharmacokinetics and Disposition Pages: 305 - 307
Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice B. Beermann H. Melander R. Dahlqvist Pharmacoepidemiology and Prescription Pages: 309 - 311
Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997 Patrick M. Craig-McFeelyNayan V. AcharyaSaad A. Shakir Pharmacoepidemiology and Prescription Pages: 313 - 320
Fatal hepatotoxicity secondary to nimesulide Giorgio MerlaniMark FoxGerd A. Kullak-Ublick Pharmacoepidemiology and Prescription Pages: 321 - 326
Antipsychotic-induced extrapyramidal syndromes I. Schillevoort A. de Boer H. Leufkens Pharmacoepidemiology and Prescription Pages: 327 - 331
Personal formularies Jane RobertsonJayne L. FryerDavid A. Henry Pharmacoepidemiology and Prescription Pages: 333 - 341
Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993–1998) in a Danish population John LarsenMorten AndersenLars F. Gram Pharmacoepidemiology and Prescription Pages: 343 - 348